Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents

• Published in: Journal of the Endocrine Society Vol. 5; no. 1; p. bvaa155
• Main Authors: Al Khalifah, Reem A, Florez, Ivan D, Zoratti, Michael J, Dennis, Brittany, Thabane, Lehana, Bassilious, Ereny
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01-01-2021
• Subjects: Analysis; Care and treatment; Contraceptives; Diabetes therapy; Drospirenone; Evaluation; Flutamide; Medical research; Medicine, Experimental; Menstruation; Meta-Analyses; Norgestimate; Risk factors; Spironolactone; Stein-Leventhal syndrome; Teenagers; Type 2 diabetes; Youth; Canada; menstrual irregularity; hirsutism; cardiometabolic; network meta-analysis; adolescents; polycystic ovarian syndrome
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvaa155

Abstract
Limited evidence on treatment options for polycystic ovarian syndrome (PCOS) has led to considerable variation in health care practices. We aimed to compare the effects of metformin and/or oral contraceptive pills (OCP) in combination with pioglitazone, spironolactone, flutamide, and lifestyle interventions among adolescents aged 11 to 19 years with PCOS. Literature searches were performed in Medline, Embase, and the Cochrane Central Register of Controlled Trials from database inception through December 2018, with no language restriction. Two reviewers screened titles and abstracts, assessed full text eligibility, and extracted information from eligible trials. Evidence was synthesized through network meta-analyses (NMA) using a Bayesian random-effects approach. We identified 37 randomized controlled trials, in which 2400 patients were randomized. NMA showed no statistically important difference among all interventions to improve menstrual regulation or body mass index. Moderate-quality evidence showed hirsutism scores were reduced by multiple interventions that included single and combination medications namely; lifestyle intervention, metformin, OCP, spironolactone, pioglitazone, metformin-OCP, metformin-spironolactone, and metformin-flutamide against placebo. Moderate-quality evidence showed OCP results in more dysglycemia compared to metformin (odds ratio, 2.98; 95% credible interval, 1.02-8.96), no intervention resulted in dysglycemia reduction. In conclusion, metformin and OCP as monotherapy or in combination with other interventions compared with placebo can reduce hirsutism scores, but none of these medications lead to effective menstrual cycle regulation or weight reduction. However, the use of OCP leads to worse cardiometabolic risk factors. Further research into new treatment options is urgently needed.
PROSPERO registration number
CRD42015016148.